Professional Documents
Culture Documents
Review Article
Overview of Platelet Physiology: Its Hemostatic
and Nonhemostatic Role in Disease Pathogenesis
Kakali Ghoshal and Maitree Bhattacharyya
Department of Biochemistry, University of Calcutta, 35 Ballygunge Circular Road, Kolkata 700019, India
Correspondence should be addressed to Maitree Bhattacharyya; bmaitree@gmail.com
Received 31 August 2013; Accepted 10 November 2013; Published 3 March 2014
Academic Editors: E. J. Benz, L. Olcay, and M. de F. Sonati
Copyright 2014 K. Ghoshal and M. Bhattacharyya. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Platelets are small anucleate cell fragments that circulate in blood playing crucial role in managing vascular integrity and regulating
hemostasis. Platelets are also involved in the fundamental biological process of chronic inflammation associated with disease
pathology. Platelet indices like mean platelets volume (MPV), platelets distributed width (PDW), and platelet crit (PCT) are useful
as cheap noninvasive biomarkers for assessing the diseased states. Dynamic platelets bear distinct morphology, where and dense
granule are actively involved in secretion of molecules like GPIIb , IIIa, fibrinogen, vWf, catecholamines, serotonin, calcium, ATP,
ADP, and so forth, which are involved in aggregation. Differential expressions of surface receptors like CD36, CD41, CD61 and
so forth have also been quantitated in several diseases. Platelet clinical research faces challenges due to the vulnerable nature of
platelet structure functions and lack of accurate assay techniques. But recent advancement in flow cytometry inputs huge progress
in the field of platelets study. Platelets activation and dysfunction have been implicated in diabetes, renal diseases, tumorigenesis,
Alzheimers, and CVD. In conclusion, this paper elucidates that platelets are not that innocent as they keep showing and thus
numerous novel platelet biomarkers are upcoming very soon in the field of clinical research which can be important for predicting
and diagnosing disease state.
1. Introduction
Platelets were discovered by Giulio Bizzozero in 1882 [1], but
for many decades the dynamic and multifunctional nature of
platelets remained a field of interest only for biologists. Anucleate, discoid platelets are the smallest blood particles which
unveil their dynamicity through their morphology. Primarily
they are associated with hemostasis, which is to initiate blood
coagulation. Although very dynamic, they usually prefer to
remain in inactive state and get activated only when a blood
vessel is damaged. But hemostasis or blood coagulation is not
the sole function of platelets; rather it is employed in several
multifunctional attributes monitoring the homeostasis of the
body. Its high sensitivity to different disease states eventually
assigned it to be one of the most accessible markers. While
keeping interactions with leukocytes and endothelial cells, it
restores its behaviour as an important inflammatory marker
[2]. Platelet reactivity for different disease pathogenesis is
widely dependent upon some biologically active markers
Coagulation Thromboxane A2
5HT
5HT
ADP
ATP
Collagen
Thrombin
GPVI
5HT2A
P2Y1
ADP
ADP
ATP
P2X1
TPa
Dense
granule
PAR4
Platelet
activation
PAR1
P2Y12
Amplification
Aggregation
Thrombin
generation
IIb 3
granule
Shape change
IIb 3
IIb 3
Fibrinogen
Coagulation factors
inammatory mediators
Figure 1: Platelet-activation mechanisms and role of the P2Y12 receptor. Platelet activation leads to dense-granule secretion of ADP, which
activates P2Y12 , inducing amplification of aggregation, procoagulant, and proinflammatory responses (adapted from Storey, 2008 [7]).
3
Platelet starts to change its shape by the formation of
pseudopods when intracellular Ca2+ concentration exceeds
a specific threshold. During shape change, platelet fibrinogen receptors (GPIIb/IIIa) are exposed and activated, and
platelet-platelet aggregation is initiated. This is also known
as primary aggregation which is reversible. However, resting
platelets are not able to bind fibrinogen. Arachidonic acid
thromboxane pathway is an important platelet activation
pathway (Figure 4). Aspirin, also known as acetylsalicylic
acid, a drug widely used in CVD, inhibits platelet aggregation
through irreversible acetylation and inactivation of COX,
resulting in blockage of TxA2 production [24, 25]. Mature
normal human platelets express only COX-1, as the anucleate
platelet cannot synthesize enzyme de novo. As a result the
effect of aspirin on them is permanent and cumulative. Thus,
the cardioprotective effect of aspirin is exerted through the
irreversible and permanent impairment of thromboxane A2 dependent platelet function, which reduces the development
of acute arterial thrombosis [26].
ADP is another important platelet activator. P2Y12 , an
ADP specific receptor, is present on the platelet membrane
and is coupled to inhibitory G-proteins and mediates ADPinduced release of Ca2+ , inhibiting adenylate cyclase and
activating the GPIIb/IIIa receptor which leads to platelet
aggregation. The thienopyridines, ticlopidine, and clopidogrel inhibit platelet activation via blockage of the P2Y12 receptor [27]. Thromboxane A2 , ADP, and other substances such
as serotonin, released from the activated platelet, provide
important positive feedback and strengthen the platelet-rich
clot initiating secondary aggregation which is irreversible
(Figure 3) [28].
Platelet response is amplified via substances released by
platelet granules which recruit other platelets and blood cells.
The platelet plug initially formed in primary hemostasis is
relatively unstable. Coagulation cascade and formation of
thrombin and fibrin prolong secondary hemostasis. During
platelet activation, platelet membrane phospholipids become
negatively charged, which facilitates coagulation activation
(e.g., FV, FVIIIa, FIXa, and FX). Binding of the prothrombinase complex (FXa, FVa, Ca2+ , and prothrombin) to the
platelet membrane occurs in this step. Further platelet activation is initiated by the formation of thrombin. These cascades
lead to the formation of red thrombus strengthening the
blood clot [29].
Intact vascular endothelium releases two major antiaggregants, prostacyclin (PGI2 ) and nitric oxide (NO), which
prevent the formation of thrombus inside the blood vessel
[31].
2.4. Platelet Function Assay. Platelets are dynamic blood
particles which can interact with each other as well as with
leukocyte and endothelial cells. Previously, platelet function
was assessed using light transmission aggregometer [32]
whose primary function was to measure the increase in light
transmission through a platelet suspension when platelets
were aggregated by an agonist. It has some major drawbacks.
First of all, the result obtained may be affected by many
variables. Secondly, the accuracy and the reproducibility of
Receptors
Present in
GPIb-IX-V complex
Family
Ligands
Comments
Platelet surface
Bernard-Soulier
syndrome
Ig superfamily
Collagen, laminin
2 1
Platelet surface
Platelet plasma
membrane
Integrins
Collagen
5 1
Fibronectin
6 1
V3
IIb 3
Laminin
Vitronectin, fibrinogen, vWf,
osteopontin
Fibrinogen, fibrin, vWf, TSP-1,
fibronectin, vitronectin
Glanzmann
thrombasthenia
CD148
Platelet surface
Tyrosine phosphatase
receptor
Unknown
Regulation of GPVI
CLEC-2
Receptors
Present in
Family
Ligands
P2Y1
Platelet plasma
membrane
G protein-coupled
receptors
ADP
P2Y12
PAR1
Thrombin
High affinity
PAR4
Low affinity
tPA
PAF receptors
Thromboxane
1-O-alkyl-2-acetyl-sn-glycero-3phosphocholine
PAF: platelet
activating factor
PGE2
Lysophosphatidic acid
Chemokine receptors
Chemokines
Vasopressin
Adenosine
b2 adrenergic receptor
Epinephrine
Serotonin receptor
Serotonin (5-hydroxytryptamin)
Dopamine receptor
Dopamine
P2 X 1
ATP
c-Mp1
Ion channel
Tyrosine kinase
receptor
Insulin receptor
Insulin
PDGF receptor
PDGF
Leptin receptor
Cytokine
Leptin
Comments
TPO
(c) Platelet receptors in the stabilization phase and in the negative regulation of platelet activation
Receptors
Present in
Family
Ligands
Stabilization
Eph receptor
Axl/Tyro3/Mer
Ephrin
Gas-6
Comments
5
(c) Continued.
Receptors
TSSC6
CD151
Present in
Platelet
granule; comes in plasma
membrane upon activation
Platelet plasma membrane
CD36
TLT-1
Ig superfamily
PEAR1
VPAC1
P-selectin
Family
Ligands
Comments
PSGL-1, GPIb, TF
Soluble
P-selectin: biomarker
Tetraspanins
PECAM-1
Ig superfamily
G6B-b
PGD2 receptor
PGE2 receptor (EP4)
G protein-coupled
receptors
Many functions
TLT-1 soluble form
correlated with DIC
Phosphorylated after
platelet contact
PACAP
PECAM-1, collagen,
glycosaminoglycans
PGI2
Prostacyclin released
from endothelial cells
PGD2
PGE2
Table 2: A comparison of endothelial and platelet properties (adapted from Warkentin et al., 2003 [21]).
Endothelium
Platelets
Life span
Daily production
Yes
Lots
Highly variable: up to 100 M
length in large vessels
Long (months to years)
Not known
Circulating
Few
No
Little but active
Diameter 4 M, volume 712 fL
(inversely proportional to platelet count)
Short (79 days)
2.5 1011
Most (normally 1/3 sequestered in spleen; may become
sequestered on activated endothelium)
Nucleus
mRNA
Cell dimensions
Origin
Storage granules
Diagnostic markers
plasma from the patients to the pathology lab or by point-ofcare (POC) platelet function test. The tests are summarized
in (Table 3).
3. Platelet Dysfunction in
Disease Pathophysiology
In recent times, platelets have emerged to be important markers for disease pathophysiology. They are multifunctional
blood particles and very important clinical targets for many
disease pathophysiology (Figure 8). Being important inflammatory markers, they play important roles in atherosclerosis
and cardiovascular disorders which are correlated with type
2 diabetes. They have profound role in tumor biology as
well as allergic inflammation. Thrombin, an agonist released
by platelets has profound role in inflammation [4144],
angiogenesis [45] and embryonic development [46, 47].
7
PMP
Monocyte
PSGL-1
PMP
CD62P
TF
MMP
CD11b
PMP
AA
PKC
COX-2
EMP
CD54
MAPK
Endothelial cell
Figure 2: Mechanism of vascular changes by platelet-derived microparticles (PMPs). PMPs activate monocytes by a reaction between Pselectin and PSGL-1 (P-selectin glycoprotein ligand-1). Activated monocytes induce expression on the cell surface of tissue factor (TF) and
CD11b. Activated monocytes also induce release of monocyte-derived microparticles (MMPs). PMPs induce COX-2 production in endothelial
cells. PMPs enhance expression of CD54 (ICAM-1) on the endothelial surface. Activated endothelial cells also induce release of endothelial
cell-derived microparticles (EMPs), enhancing adhesion between endothelial cells and monocytes. Finally, monocytes induce migration of
endothelial cells, resulting in vascular changes. Abbreviations: arachidonic acid (AA); protein kinase C (PKC); mitogen-activated protein
kinase (MAPK) (adapted from Nomura, 2001 [8]).
Primary hemostasis
Vasoconstriction
Secondary hemostasis
Coagulation (fibrin formation) fibrinolysis
Repair process
Wound healing
Arachidonic acid
Cyclooxygenase
Prostaglandin G2 (PGG2 )
Prostacyclin (PGI2 )
Prostaglandin H2 (PGH2 )
TxA2 -synthase
Thromboxane A2 (TxA2 )
Thromboxane B2 (TxB2 )
11-Dehydro-TxB2
2,3-dinor-TxB2
4.3. Changes in Platelet Membrane Fluidity. Change in membrane fluidity has been assigned to the impairment of platelet
functions since membrane fluidity can modulate cell function, and reduced membrane fluidity in cholesterol- enriched
platelets is associated with platelet hypersensitivity to different agonists [65]. Due to glycation of membrane proteins,
platelet membrane fluidity has been grossly impaired in
diabetes. Decreased membrane fluidity of these platelets is
attributed to an increased cholesterol-phospholipid molar
ratio in platelet membranes. Reduced membrane fluidity
is associated with hypersensitivity to thrombin in intact
platelets from diabetic subjects [66, 67].
4.4. Altered Expression of Platelet Agonists. The number and
adhesiveness of several platelet specific surface glycoprotein
receptors (GP) are significantly enhanced in diabetic subjects.
CD40 ligand on platelets has been correlated with HbA1c
concentrations. An upregulation of the CD40-CD40 ligand
system has been observed in patients with DM [68] along
with an increase in GPIIb/IIIa, vWf, GPIa/IIa, P-selectin
(CD62), and CD63 [6972]. Patients suffering from ischemic
9
Subendothelium
Collagen vWf
GPVI
GPIIb/IIIa
ADP Fibrinogen TxA2
GPIIb/IIIa
GPIIb/IIIa
Fibrinogen
GPIIb/IIIa
GPIb-IX-V
Shape change
Primary aggregation
Adhesion
Secretion
Secondary aggregation
Figure 5: After an injury in the vessel wall, activation of platelets begins to start. It involves its adhesion to the subendothelium surface.
Interaction between receptors like GPIb-V-IX, GPIa-IIa, and subendothelial compounds like vWf and collagen triggers the release of platelet
granule contents accelerating aggregate formation.
Vasoconstrictive substances
ADP
en
og
in IIa
br b/I
Fi GPII
Cytokines
Activation
Ca2+
Platelet
Conformational
changes
A1
A3
GP
IIb
/II
Ia
GPIb-IX-V
(GPIb)
RGD
RGD
FVW
GPIIb/IIIa
A1
Collagen VI
A3 RGDRGD
Collagen IIII
Collagen
Extracellular matrix
Figure 6: Diagram illustrating the role of von Willebrand factor (vWf) in platelet adhesion. High flow rates induce conformational changes
in vWf allowing interaction of its A3 domain with matrix collagen. This induces a conformational change in the A1 domain, thereby allowing
interaction with glycoprotein (GP) platelet receptor Ib-IX-V. This interaction stimulates calcium release, subsequent platelet activation, and
subsequent conformational change of the fibrinogen receptor (GPIIb/IIIa), which can interact with fibrinogen and vWf to favor the interaction
between platelets (platelet aggregation process). ADP indicates adenosine diphosphate; RGD and Arg-Gly-Asp are amino acid sequences
(adapted from Badimon et al., 2009 [30]).
1000
100
100
10
CD62PE
1000
(128 128)
(128 128)
CD62PE
10
10
-1
-1
1
10
100
1000
CD61FITC
CD62P expression 45%
10
100
1000
CD61FITC
CD62P expression 17%
(a)
(b)
Figure 7: Flow cytometric detection of P-selectin in (a) diabetic patient and (b) nondiabetic patient (adapted from Saad et al., 2011 [34]).
Platelet
functions
Inammation
Atherosclerosis
Allergic asthma
Renal disease
Chemotaxis
Platelet-leukocyte
interactions
Tumor biology
Tumor growth
Tumor killing
Tumor metastasis
Host defense
Phagocytosis/internalisation of viruses
and bacteria
Killing of bacteria
Release of platelet microbicidal proteins
Superoxide production
11
capillaries [124]. Both intrinsic platelet abnormalities and
impaired platelet-vessel wall interaction can contribute to
platelet dysfunction [125]. In renal failure, the normal activation process of the platelets to form aggregates is impaired.
5.3. Cancer and Tumorigenesis. Platelet plays versatile role in
cancer progression. The procoagulant environment provided
by platelets can secure the coagulation of cancer cells,
protecting them from immune system, thus prompting the
formation of tumors [126]. Platelets facilitate tumor cell
migration and invasiveness, prompting metastasis. It has
been reported in both breast and ovarian cancer that platelets
increase the invasiveness of cancer cells which can induce the
further progression of the disease [127129]. Moreover, tumor
cells also have the ability to aggregate platelets [130], further
increasing the chance of inducing metastasis. Activation of
platelets and regulation of other cells have been controlled by
thrombin by means of G protein-coupled protease-activated
receptors (PARs) [131]. Researchers have shown that thrombin signaling also contributes hugely to the progression of
tumorigenesis and angiogenesis [132].
5.4. Alzheimers Disease. Platelet dysfunction has been also
implicated in Alzheimers disease (AD), which is the most
common form of dementia. Platelet can store a huge amount
of amyloid precursor protein (APP); recent finding shows
that platelet APP metabolism may accumulate A in the
brain and its vasculature through the blood brain barrier
[133]. Platelet -granules store RANTES, an inflammatory
signaling molecule whose secretion from PBMC has been
reported to increase in AD [134]. The fluidity of the hydrocarbon region of platelet membranes from the AD patients is
significantly higher than that of control group [135]. Platelet
secretases activities and COX enzyme activity (which is also
a component in APP secretion pathway) have been impaired
in platelets of AD patients, thus making this blood particle a
suitable marker of this disease [136].
5.5. Liver Disease. Quantitative and qualitative platelet
defects, hyperfibrinolysis, accelerated intravascular coagulation, and decreased synthesis of clotting and inhibitor factors
are well observed in both acute and chronic liver diseases
[137]. As most coagulation factors except vWf are synthesized
by liver parenchymal cells, and livers reticuloendothelial
system plays crucial role in the clearance of activation
products, a defect in liver function may alter hemostasis
[138, 139]. Not only functions but platelet numbers also have
been reported to decrease in liver diseases [140]. It has been
reported that platelet transfusion can improve liver function
in patients with chronic liver disease and cirrhosis [141].
Platelets morphological parameters have been also reported
to alter in liver diseases [142], thus providing a platform for
platelet research in liver diseases.
6. Conclusion
Biomarkers are now emerging with immense scientific and
clinical value through the whole journey of the disease
12
process. Before diagnosis, markers can be used for prediction,
screening, and risk assessment. During diagnosis, markers
can determine staging, grading, and selection of initial drug
therapy. During treatment, markers are used to monitor
the prognosis of therapy or to select additional treatment
needed. Platelet indices indicating differential dysfunction,
hyperactivation, aggregation, or adhesion are capable of
expressing the characters of disease pathogenesis. Accurate
determination of platelet indices is cost effective and their
impaired function can be correlated with the inflammation
involved in diseased state. Thus, an attempt to identify
different platelet biomarkers is of significant impact on the
global scene of clinical application and development.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgement
The authors acknowledge Council of Scientific and Industrial
Research, Government of India, for providing research fellowship to Ms. K. Ghoshal.
References
[1] D. Ribatti and E. Crivellato, Giulio Bizzozero and the discovery
of platelets, Leukemia Research, vol. 31, no. 10, pp. 13391341,
2007.
[2] C. Cerletti, C. Tamburrelli, B. Izzi, F. Gianfagna, and G. de Gaetano, Platelet-leukocyte interactions in thrombosis, Thrombosis Research, vol. 129, no. 3, pp. 263266, 2012.
[3] A. I. Vinik, T. Erbas, T. Sun Park, R. Nolan, and G. L. Pittenger,
Platelet dysfunction in type 2 diabetes, Diabetes Care, vol. 24,
no. 8, pp. 14761485, 2001.
[4] G. Sharma and J. S. Berger, Platelet activity and cardiovascular
risk in apparently healthy individuals: a review of the data,
Journal of Thrombosis and Thrombolysis, vol. 32, no. 2, pp. 201
208, 2011.
[5] A. D. Michelson, Flow cytometry: a clinical test of platelet
function, Blood, vol. 87, no. 12, pp. 49254936, 1996.
[6] H. M. Rinder, P latelet function testing by flow cytometry,
Clinical Laboratory Science, vol. 11, pp. 365372, 1998.
[7] R. F. Storey, New developments in antiplatelet therapy, European Heart Journal, Supplement, vol. 10, pp. D30D37, 2008.
[8] S. Nomura, Function and clinical significance of plateletderived microparticles, International Journal of Hematology,
vol. 74, no. 4, pp. 397404, 2001.
[9] P. Blair and R. F. laumenhaft, P latelet alpha-granules: basic
biology and clinical correlates, Blood Reviews, vol. 23, pp. 177
189, 2009.
[10] S. Offermanns, Activation of platelet function through G
protein-coupled receptors, Circulation Research, vol. 99, no. 12,
pp. 12931304, 2006.
[11] J. W. Heemskerk, E. M. Bevers, and T. Lindhout, P latelet activation and bloo d coagulation, Thrombosis and Haemostasis,
vol. 88, pp. 186193, 2002.
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
13
[46] M. J. Paidas, M. J. Haut, and C. J. Lockwood, Platelet disorders
in pregnancy: implications for mother and fetus, Mount Sinai
Journal of Medicine, vol. 61, no. 5, pp. 389403, 1994.
[47] J. L. Clements, J. R. Lee, B. Gross et al., Fetal hemorrhage and
platelet dysfunction in SLP-76-deficient mice, Journal of Clinical Investigation, vol. 103, no. 1, pp. 1925, 1999.
[48] M. R. Hayden, Islet amyloid, metabolic syndrome, and the
natural progressive history of type 2 diabetes mellitus, Journal
of the Pancreas, vol. 3, no. 5, pp. 126138, 2002.
[49] D. Parmar, K. Vidja, and B. Ghugare, Impact of duration of
diabetes and age: on lipid profile and glycaemic control in type
2 diabetic patients, Journal of International Medical Research,
vol. 2, no. 1, pp. 6972, 2013.
[50] W. T. Cade, Diabetes-related microvascular and macrovascular
diseases in the physical therapy setting, Physical Therapy, vol.
88, no. 11, pp. 13221335, 2008.
[51] S. Lamon-Fava, P. W. F. Wilson, and E. J. Schaefer, Impact of
body mass index on coronary heart disease risk factors in men
and women: the Framingham Offspring Study, Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 16, no. 12, pp. 15091515,
1996.
[52] A. Chakraborty and M. Bhattacharyya, Diabetes, hypertension
and cardiovascular diseasean unsolved enigma, in Phytotherapy in the Management of Diabetes and Hypertension, pp. 85119,
2012.
[53] A. Saha, S. Adak, S. Chowdhury, and M. Bhattacharyya,
Enhanced oxygen releasing capacity and oxidative stress in
diabetes mellitus and diabetes mellitus-associated cardiovascular disease: a comparative study, Clinica Chimica Acta, vol. 361,
no. 1-2, pp. 141149, 2005.
[54] S. Adak, S. Chowdhury, and M. Bhattacharyya, Dynamic and
electrokinetic behavior of erythrocyte membrane in diabetes
mellitus and diabetic cardiovascular disease, Biochimica et
Biophysica Acta, vol. 1780, no. 2, pp. 108115, 2008.
[55] A. Hughes, B. A. McVerry, L. Wilkinson, A. H. Goldstone,
D. Lewis, and A. Bloom, Diabetes, a hypercoagulable state?
Haemostatic variables in newly diagnosed type 2 diabetic
patients, Acta Haematologica, vol. 69, no. 4, pp. 254259, 1983.
[56] M. H. Rosove, H. J. L. Frank, and S. S. L. Harwig, Plasma thromboglobulin, platelet factor 4, fibrinopeptide A, and other
hemostatic functions during improved, short-term glycemic
control in diabetes mellitus, Diabetes Care, vol. 7, no. 2, pp. 174
179, 1984.
[57] R. de Cristofaro, B. Rocca, E. Vitacolonna et al., Lipid and
protein oxidation contribute to a prothrombotic state in patients
with type 2 diabetes mellitus, Journal of Thrombosis and
Haemostasis, vol. 1, no. 2, pp. 250256, 2003.
[58] R. K. Mayfield, P. V. Halushka, and H. J. Wohltmann, Platelet
function during continuous insulin infusion treatment in
insulin-dependent diabetic patients, Diabetes, vol. 34, no. 11, pp.
11271133, 1985.
[59] P. V. Halushka, R. Mayfield, H. J. Wohltmann et al., Increased
platelet arachidonic acid metabolism in diabetes mellitus,
Diabetes, vol. 30, no. 2, pp. 4448, 1981.
[60] L. Tomaselli, C. Cerletti, G. de Gaetano, A. Notarbartolo, G.
Davi, and M. Pupillo, Normal platelet function, but increased
platelet activation in vivo in diabetic patients, Thrombosis and
Haemostasis, vol. 64, no. 4, p. 604, 1990.
[61] P. V. Halushka, R. C. Rogers, C. B. Loadholt, and J. A. Colwell,
Increased platelet thromboxane synthesis in diabetes mellitus,
Journal of Laboratory and Clinical Medicine, vol. 97, no. 1, pp.
8796, 1981.
14
[62] J. W. D. McDonald, J. Dupre, N. W. Rodger, M. C. Champion,
C. D. Webb, and M. Ali, Comparison of platelet thromboxane
synthesis in diabetic patients on conventional insulin therapy
and continuous insulin infusions, Thrombosis Research, vol. 28,
no. 6, pp. 705712, 1982.
[63] G. Davi, I. Catalano, M. Averna et al., Thromboxane biosynthesis and platelet function in type II diabetes mellitus, The
New England Journal of Medicine, vol. 322, no. 25, pp. 17691774,
1990.
[64] G. Dav`, G. Ciabattoni, A. Consoli et al., In vivo formation of
8-iso-prostaglandin and platelet activation in diabetes mellitus:
effects of improved metabolic control and vitamin E supplementation, Circulation, vol. 99, no. 2, pp. 224229, 1999.
[65] P. D. Winocour, M. Bryszewska, C. Watala et al., Reduced
membrane fluidity in platelets from diabetic patients, Diabetes,
vol. 39, no. 2, pp. 241244, 1990.
[66] P. D. Winocour, C. Watala, and R. L. Kinglough-Rathbone,
Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phospholipid
molar ratio in isolated platelet membranes from diabetic and
control subjects, Thrombosis and Haemostasis, vol. 67, no. 5, pp.
567571, 1992.
[67] P. D. Winocour, C. Watala, D. W. Perry, and R. L. KinloughRathbone, Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins, Thrombosis and
Haemostasis, vol. 68, no. 5, pp. 577582, 1992.
[68] Y. Jinchuan, W. Zonggui, C. Jinming, L. Li, and K. Xiantao,
Upregulation of CD40-CD40 ligand system in patients with
diabetes mellitus, Clinica Chimica Acta, vol. 339, no. 1-2, pp. 85
90, 2004.
[69] D. Tschoepe, P. Roesen, L. Kaufmann et al., Evidence for abnormal platelet glycoprotein expression in diabetes mellitus, European Journal of Clinical Investigation, vol. 20, no. 2, pp. 166170,
1990.
[70] D. Tschoepe, E. Driesch, B. Schwippert, H.-K. Nieuwenhuis,
and F. A. Gries, Exposure of adhesion molecules on activated
platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia, Diabetes, vol. 44, no. 8, pp. 890
894, 1995.
[71] B. Jilma, P. Fasching, C. Ruthner et al., Elevated circulating Pselectin in insulin dependent diabetes mellitus, Thrombosis and
Haemostasis, vol. 76, no. 3, pp. 328332, 1996.
[72] N. Eibl, W. Krugluger, G. Streit, K. Schrattbauer, P. Hopmeier,
and G. Schernthaner, Improved metabolic control decreases
platelet activation markers in patients with type-2 diabetes,
European Journal of Clinical Investigation, vol. 34, no. 3, pp. 205
209, 2004.
[73] F. Laghrissi-Thode, W. R. Wagner, B. G. Pollock, P. C. Johnson, and M. S. Finkel, Elevated platelet factor 4 and thromboglobulin plasma levels in depressed patients with
ischemic heart disease, Biological Psychiatry, vol. 42, no. 4, pp.
290295, 1997.
[74] S. G. Thompson, J. Kienast, S. D. M. Pyke et al., Hemostatic
factors and the risk of myocardial infarction or sudden death
in patients with angina pectoris, The New England Journal of
Medicine, vol. 332, no. 10, pp. 635641, 1995.
[75] M. L. Balestrieri, L. Servillo, A. Esposito et al., Poor glycaemic
control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing S IRT1 signalling via plateletactivating factor receptor activation, Diabetologia, vol. 56, pp.
162172, 2013.
15
[110] I. Fleming, C. Schulz, B. Fichtlscherer, B. E. Kemp, B. Fisslthaler,
and R. Busse, AMP-activated protein kinase (AMPK) regulates
the insulin-induced activation of the nitric oxide synthase in
human platelets, Thrombosis and Haemostasis, vol. 90, no. 5,
pp. 863871, 2003.
[111] V. Randriamboavonjy, J. Schrader, R. Busse, and I. Fleming,
Insulin induces the release of vasodilator compounds from
platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway, Journal of Experimental Medicine, vol. 199, no. 3, pp. 347
356, 2004.
[112] T. Yamaguchi, K. Kadono, T. Tetsutani, and K. Yasunaga,
Platelet free Ca2+ concentration in non-insulin-dependent
diabetes mellitus, Diabetes Research, vol. 18, no. 2, pp. 8994,
1991.
[113] W. L. Dean, D. Chen, P. C. Brandt, and T. C. Vanaman, Regulation of platelet plasma membrane Ca2+ -ATPase by cAMPdependent and tyrosine phosphorylation, Journal of Biological
Chemistry, vol. 272, no. 24, pp. 1511315119, 1997.
[114] G. Cella, N. Scattolo, C. Vio et al., Platelet factor 4 (PF4) and
heparin released platelet factor 4 (HR-PF4) in diabetes mellitus.
Effect of the duration of the disease, Folia Haematologica, vol.
113, no. 5, pp. 646654, 1986.
[115] S. Sacchi, G. Curci, L. Piccinini et al., P latelet alpha granule
release in diabetes mellitus, Scandinavian Journal of Clinical &
Laboratory Investigation, vol. 45, pp. 165168, 1985.
[116] V. Henn, S. Steinbach, K. Buchner, P. Presek, and R. A.
Kroczek, The inflammatory action of CD40 ligand (CD154)
expressed on activated human platelets is temporally limited by
coexpressed CD40, Blood, vol. 98, no. 4, pp. 10471054, 2001.
[117] C. Gisinger, J. Jeremy, P. Speiser, D. Mikhailidis, P. Dandona,
and G. Schernthaner, Effect of vitamin E supplementation on
platelet thromboxane A2 production in Type I diabetic patients.
Double-blind crossover trial, Diabetes, vol. 37, no. 9, pp. 1260
1264, 1988.
[118] M. Sacco, F. Pellegrini, M. C. Roncaglioni, F. Avanzini, G.
Tognoni, and A. Nicolucci, Primary prevention of cardiovascular events with low dose aspirin and vitamin E in type 2 diabetic
patients: results of the Pimary Prevention Project (PPP) trial,
Diabetes Care, vol. 26, no. 12, pp. 32643272, 2003.
[119] I. Chung and G. Y. H. Lip, Platelets and heart failure, European
Heart Journal, vol. 27, no. 22, pp. 26232631, 2006.
[120] J. Mehta and P. Mehta, Platelet function studies in heart disease.
VI. Enhanced platelet aggregate formation activity in congestive
heart failure: inhibition by sodium nitroprusside, Circulation,
vol. 60, no. 3, pp. 497503, 1979.
[121] G. Y. H. Lip, G. D. O. Lowe, M. J. Metcalfe, A. Rumley, and F.
G. Dunn, Effects of warfarin therapy on plasma fibrinogen,
von Willebrand factor, and fibrin D-dimer in left ventricular
dysfunction secondary to coronary artery disease with and
without aneurysms, American Journal of Cardiology, vol. 76, no.
7, pp. 453458, 1995.
[122] I. Chung, A. Choudhury, and G. Y. H. Lip, Platelet activation
in acute, decompensated congestive heart failure, Thrombosis
Research, vol. 120, no. 5, pp. 709713, 2007.
[123] A. Shah, G. Passacquale, E. Gkaliagkousi, J. Ritter, and A. Ferro,
Platelet nitric oxide signalling in heart failure: role of oxidative
stress, Cardiovascular Research, vol. 91, no. 4, pp. 625631, 2011.
[124] P. Boccardo, G. Remuzzi, and M. Galbusera, Platelet dysfunction in renal failure, Seminars in Thrombosis and Hemostasis,
vol. 30, no. 5, pp. 579589, 2004.
16
[125] D. Kaw and D. Malhotra, Platelet dysfunction and end-stage
renal disease, Seminars in Dialysis, vol. 19, no. 4, pp. 317322,
2006.
[126] C. Belloc, H. Lu, C. Soria, R. Fridman, Y. Legrand, and S.
Menashi, The effects of platelets on invasiveness and protease
production of human mammary tumor cells, International
Journal of Cancer, vol. 60, no. 3, pp. 413417, 1995.
[127] J. M. Lewalle, V. Castronovo, G. Goffinet, and J. M. Foidart,
Malignant cell attachment to endothelium of ex vivo perfused
human umbilical vein. Modulation by platelets, plasma and
fibronectin, Thrombosis Research, vol. 62, no. 4, pp. 287298,
1991.
[128] G. C. Haralabopoulos, D. S. Grant, H. K. Kleinman, and M. E.
Maragoudakis, Thrombin promotes endothelial cell alignment
in Matrigel in vitro and angiogenesis in vivo, American Journal
of PhysiologyCell Physiology, vol. 273, no. 1, pp. C239C245,
1997.
[129] N. M. Bambace and C. E. Holmes, The platelet contribution
to cancer progression, Journal of Thrombosis and Haemostasis,
vol. 9, no. 2, pp. 237249, 2011.
[130] S. Jain, J. Harris, and J. Ware, P latelets: linking hemostasis and
cancer, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
30, pp. 23622367, 2010.
[131] J. E. Freedman, Thrombin, thrombomodulin, and extracellular
signal-regulated kinases regulating cellular proliferation, Circulation Research, vol. 88, no. 7, pp. 651653, 2001.
[132] W. Ruf and B. M. Mueller, Thrombin generation and the pathogenesis of cancer, Seminars in Thrombosis and Hemostasis, vol.
32, supplement 1, pp. 6168, 2006.
[133] S. Catricala, M. Torti, and G. Ricevuti, A lzheimer disease and
platelets: hows that relevant, Immunity & Ageing, vol. 9, p. 20,
2012.
[134] C. Iarlori, D. Gambi, F. Gambi et al., Expression and production
of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimers disease, Experimental
Gerontology, vol. 40, no. 7, pp. 605611, 2005.
[135] G. S. Zubenko, B. M. Cohen, C. F. Reynolds III, F. Boller, I.
Malinakova, and N. Keefe, Platelet membrane fluidity in
Alzheimers disease and major depression, American Journal of
Psychiatry, vol. 144, no. 7, pp. 860868, 1987.
[136] C. I. Prodan, E. D. Ross, J. A. Stoner, L. D. Cowan, A. S. Vincent,
and G. L. Dale, Coated-platelet levels and progression from
mild cognitive impairment to Alzheimer disease, Neurology,
vol. 76, no. 3, pp. 247252, 2011.
[137] L. Amitrano, M. A. Guardascione, V. Brancaccio, and A.
Balzano, Coagulation disorders in liver disease, Seminars in
Liver Disease, vol. 22, no. 1, pp. 8396, 2002.
[138] E. F. Mammen, Coagulation abnormalities in liver disease,
Hematology/Oncology Clinics of North America, vol. 6, no. 6, pp.
12471258, 1992.
[139] P. A. McCormick and K. M. Murphy, Splenomegaly, hypersplenism and coagulation abnormalities in liver disease, Best
Practice and Research, vol. 14, no. 6, pp. 10091031, 2000.
[140] G. G. C. Hugenholtz, R. J. Porte, and T. Lisman, The platelet
and platelet function testing in liver disease, Clinics in Liver
Disease, vol. 13, no. 1, pp. 1120, 2009.
[141] T. Maruyama, S. Murata, K. Takahashi et al., Platelet transfusion improves liver function in patients with chronic liver disease and cirrhosis, The Tohoku Journal of Experimental
Medicine, vol. 229, pp. 213220, 2013.
MEDIATORS
of
INFLAMMATION
The Scientific
World Journal
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Gastroenterology
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Journal of
Diabetes Research
Volume 2014
Volume 2014
Volume 2014
International Journal of
Journal of
Endocrinology
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com
Disease Markers
Volume 2014
Volume 2014
PPAR Research
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Volume 2014
Journal of
Obesity
Journal of
Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Evidence-Based
Complementary and
Alternative Medicine
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Volume 2014
Journal of
Oncology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Volume 2014
Parkinsons
Disease
Computational and
Mathematical Methods
in Medicine
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
AIDS
Behavioural
Neurology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Volume 2014
Volume 2014